I
n the December 2011 issue of Diabetes, Kim et al. (1) reported that 4-1BB (CD137/TNFRSF9) deficiency protected against high-fat diet-induced obesity, glucose intolerance, and fatty liver disease. They found that 4-1BB deficiency reduced number and activation of macrophages/CD8
1 T cells/Th1 cells into adipose tissue, reduced circulating proinflammatory cytokines, and improved insulin sensitivity/liver pathology with respect to wild-type (WT) animals fed the same diet. This is an important advance in the field because antagonism of the 4-1BB/4-1BB ligand interaction (e.g., modulating its expression, blocking receptor/ligand interaction, and interfering signaling) could help reduce macrophage infiltration and adipose tissue inflammation in obesity. However, in an article published by the same laboratories in 2010 in Endocrinology (2), they found that 4-1BB stimulation with an agonistic antibody reduced weight gain and adiposity, increased energy expenditure, and improved insulin tolerance and fatty liver disease in mice fed a high-fat diet and genetically obese mice. The authors suggested that these effects would have been caused by 4-1BB-induced expansion/activation of CD8 1 T cells and consequent increased energy expenditure. We are puzzled and wish to understand this apparent discrepancy between these two elegant studies (1, 2) and why the first study was not discussed in the Diabetes article, which would help us understand the rationale of these apparently opposite results between these studies.
Inflammation and dysfunction of adipose tissue have emerged as important targets to reduce systemic inflammation and insulin resistance associated with obesity (3). As supported by an extensive body of evidence, most of the inflammatory cytokines produced by inflamed adipose tissue derives from fat-infiltrating and classically activated M1 macrophages (3). This infiltration and activation of macrophages into the metabolically stressed adipose tissue in obesity play critical roles in metabolic alterations associated to obesity (3). The work by Nishimura et al. (4) To facilitate the advancement in the field, it is necessary to have a clearer picture of how agonists or antagonists of 4-1BB and/or 4-1BB ligand change macrophage recruitment and activation in the metabolically stressed adipose tissue in obesity. Understanding of these processes will ensure mechanism-based interventions to reduce macrophage infiltration and consequent adipose tissue inflammation-a leading cause of metabolic complications of obesity.
